HOME >> BIOLOGY >> NEWS
Highly specific biological agents attack mechanisms of treatment resistance

Conjugated Herceptin dramatically improves Herceptin-alone results against breast cancer

A Herceptin-DM1 conjugate produced complete regressions in mice bearing human breast cancer where Herceptin alone slowed tumor growth, according to new data presented here today.

Approximately 25% of all breast cancer patients carry extra copies of HER2, a protein that instructs their tumor to grow. Herceptin is a monoclonal antibody that binds to HER2 and suppresses its growth signal.

Were looking for ways to enhance the clinical benefit of Herceptin, such as attaching to it agents that might be synergistic, such as DM1, a compound that blocks cell division, said Ralph H. Schwall, Ph.D., senior scientist at Genentech, Inc., South San Francisco, CA, and lead author of the current study

In this study, Herceptin was chemically bound to DM1 and tested against three different experimental breast cancer systems that have extra copies of HER2. In the first two, which used human breast cancer cells growing in mice, Herceptin-DM1 resulted in the complete disappearance of all tumors, whereas Herceptin as a single agent slowed tumor growth but did not cause regression.

The third experiment used a breast tumor from a transgenic mouse engineered to have high levels of HER2. The growth of this mouse tumor did not respond to Herceptin, but Herceptin-DM1 caused the tumor to shrink by more than 90%, indicating that Herceptin-DM1 can work in a tumor that is resistant to Herceptin. Tumors began to regrow four to six weeks after the final dose of Herceptin-DM1, but regressed again when retreated with Herceptin-DM1.

Genentech manufactures Herceptin and partnered with ImmunoGen, Inc., of Cambridge, MA, to develop the linked molecule. Were pursuing additional animal studies to get a realistic safety profile of this conjugate, Dr. Schwall said.

DM1 is a member of the maytansine family of tubulin-blocking compounds. Tubuli
'"/>

Contact: Peter Vigliarolo
pvigliarolo@cwg.com
212-886-2200
American Association for Cancer Research
31-Oct-2001


Page: 1 2 3 4 5 6

Related biology news :

1. Leibniz Prize Winners 1999 - Most Highly Endowed German Promotional Prize For Ten Scientists
2. Veterans with Gulf War syndrome have damage in specific, primitive portion of nervous system
3. Resveratrol synthase uncovered: Cyclization specificity of type III polyketide synthases
4. Anticancer drug zebularine specifically targets tumor cells
5. PCB breakdown in rivers depends on sediment-specific bacteria, find Carnegie Mellon U. scientists
6. X marks the spot: Vector insertion is viral specific
7. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
8. Sex-specific differences in gene expression related to drug metabolism and hypertension
9. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
10. Lack of specific brain protein causes marked deficits in learning, memory
11. HIV exhausts the immune system through chronic non-specific activation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/15/2016)... Yissum Research Development Company of the ... the Hebrew University, announced today the formation of ... various human biological indicators. Neteera Technologies has completed its ... investors. ... electromagnetic emissions from sweat ducts, enables reliable and speedy ...
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/8/2016)... N.C. , March 8, 2016   ... sensor technology, today announced it has secured $11M ... by GII Tech, a new venture fund being ... with additional participation from existing investors TDF Ventures ... the funds to continue its triple-digit growth and ...
Breaking Biology News(10 mins):
(Date:5/6/2016)... AUSTIN, Texas , May 6, 2016 ... risk drug addiction from prescription pain medication when treating ... in adult stem cell therapy, doctors can go right ... potentially dangerous drugs. MedRebels, an educational organization, provides physician ... therapy and a search feature to find physicians across ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... on a definitive agreement to acquire Algynomics, a research-stage pain diagnostics company. The ... to identify individuals at increased risk for the development of chronic pain, which ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS ... of its first three targets, it has identified a fourth in a series ... in the development and progression of Alzheimer’s disease (AD). , “This ...
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the ... partnership with McGill University . The partnership is designed to advance research in ... to help patients in pain. With the new agreement, researchers at Proove Biosciences are ...
Breaking Biology Technology:
Cached News: